Combating anoikis resistance: bioactive compounds transforming prostate cancer therapy
Authors:
- 14 May 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 35 (8) , 687-697
Abstract
The study aims to discuss the challenges associated with treating prostate cancer (PCa), which is known for its complexity and drug resistance. It attempts to find differentially expressed genes (DEGs), such as those linked to anoikis resistance and circulating tumor cells, in PCa samples. This study involves analyzing the functional roles of these DEGs using gene enrichment analysis, and then screening of 102 bioactive compounds to identify a combination that can control the expression of the identified DEGs. In this study, 53 DEGs were identified from PCa samples including anoikis-resistant PCa cells and circulating tumor cells in PCa. Gene enrichment analysis with regards to functional enrichment of DEGs was performed. An inclusive screening process was carried out among 102 bioactive compounds to identify a combination capable of affecting and regulating the expression of selected DEGs. Eventually, gastrodin, nitidine chloride, chenodeoxycholic acid, and bilobalide were selected, as their combination demonstrated ability to modulate expression of 50 out of the 53 genes targeted. The subsequent analysis focused on investigating the biological pathways and processes influenced by this combination. The findings revealed a multifaceted and multidimensional approach to tumor regression. The combination of bioactive compounds exhibited effects on various genes including those related to production of inflammatory cytokines, cell proliferation, autophagy, apoptosis, angiogenesis, and metastasis. The current study has made a valuable contribution to the development of a combination of bioactive natural compounds that can significantly impede the development of treatment resistance in prostate tumor while countering the tumors’ evasion of the immune system. The implications of this study are highly significant as it suggests the creation of an enhanced immunotherapeutic, natural therapeutic concoction with combinatorial potential.Keywords
This publication has 81 references indexed in Scilit:
- Understanding and targeting anoikis in metastasis for cancer therapiesCell Biology International, 2022
- Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironmentThe Prostate, 2021
- Pharmacological basis of tanshinone and new insights into tanshinone as a multitarget natural product for multifaceted diseasesBiomedicine & Pharmacotherapy, 2020
- Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment2020
- Design of Natural‐Product‐Inspired Multitarget Ligands by Machine LearningChemMedChem, 2019
- Downregulation of NDR1 contributes to metastasis of prostate cancer cells via activating epithelial‐mesenchymal transitionCancer Medicine, 2018
- The challenge of drug resistance in cancer treatment: a current overviewClinical & Experimental Metastasis, 2018
- Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approachesCellular and Molecular Life Sciences, 2016
- Mechanisms navigating the TGF-β pathway in prostate cancerAsian Journal of Urology, 2015
- Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cellsApoptosis, 2010